00:41 , Apr 6, 2019 |  BC Extra  |  Politics & Policy

CFIUS drawing line in sand on personal data

The Trump administration has further reinforced which kinds of life science investments will be off limits for foreign investors, as reports emerge that CFIUS is compelling two more Chinese firms to relinquish control over companies...
02:31 , Mar 15, 2019 |  BC Innovations  |  Product Development

The microbiome universe in two maps

In its “big bang” over the last decade, the universe of microbiome therapeutics has expanded far beyond its origins of fecal transplants, used primarily for C. difficile . Mapping biotech activity reveals a broadening range...
05:01 , Feb 15, 2019 |  BC Extra  |  Financial News

Stealth Bio prices $78M IPO at bottom end of range

Stealth BioTherapeutics Corp. (NASDAQ:MITO) closed down $0.10 to $11.90 Friday after raising $78 million in its IPO. Late Thursday, the company priced more ADSs than anticipated at the bottom end of its proposed range. The...
05:21 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

Stealth BioTherapeutics Corp. (Newton, Mass.) proposed an IPO on NASDAQ late on Dec. 28, less than six months after filing to list on the Hong Kong stock exchange. The prospectus filed with the SEC on...
19:24 , Dec 30, 2018 |  BC Extra  |  Financial News

Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

Stealth BioTherapeutics Corp. (Newton, Mass.) proposed an IPO on NASDAQ late Friday, less than six months after filing to list on the Hong Kong stock exchange. The prospectus filed with the SEC on Friday does...
23:20 , Dec 18, 2018 |  BC Extra  |  Company News

Management tracks: AbbVie, Semma, Ziopharm

AbbVie Inc. (NYSE:ABBV) unveiled a new executive leadership team. It includes EVP of R&D and CSO Michael Severino, who will become vice chairman and president and be responsible for R&D, HR, operations and the corporate...
03:53 , Sep 21, 2018 |  BC Innovations  |  Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
03:06 , Aug 8, 2018 |  BC Extra  |  Financial News

BeiGene dips slightly in Hong Kong debut

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) slipped HK$1 to HK$107 in its first day of trading on the Hong Kong exchange Wednesday. Last week, the company raised HK$7.1 billion ($902.7 million) by pricing its Hong Kong listing...
00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
17:36 , Aug 3, 2018 |  BC Extra  |  Financial News

Ascletis ends first trading week on downturn

Ascletis Pharma Inc. (HKSE:1672) sank HK$1.84 (16%) to HK$10.02 on Friday, ending its first week of trading down 28% from its IPO price of HK$14. This week, Ascletis became the first biotech to go public...